Quatrefolic Reduces Homocysteine
What is Quatrefolic?
Man-made folic acid, contained in supplements and added to foods is not biologically active and needs to be converted into the metabolically active 5-methyltetrahydrofolate (5-MTHF) through a multi-step process where the enzyme methylenetetrahydrofolate reductase (MTHFR) owns a key role. Folate status in pregnancy is a critical factor for proper foetal development. Humans cannot synthesise folate and pregnant women rarely consume adequate quantities of it through their diet, therefore folate is required to prevent NTDs (neural tube defects). Some individuals, due to their unique genetic patterns and expression, have a polymorphism enzyme and do not produce adequate or effective MTHFR. Quatrefolic® is structurally analogous to the reduced and active form of folate so it completely bypasses the “damaged” MTHFR conversion step and delivers a “finished” folate the body can immediately use without any kind of metabolisation. Pregnant women with MTHFR genetic polymorphisms have an increased risk of many deleterious defects, such as NTDs, cleft palate, attention deficit hyperactivity disorder and low birth weight as well as pregnancy loss and preeclampsia. Quatrefolic® may be particularly useful during preconception, pregnancy and also lactation because it provides the “natural” and “bioactive” dose of folate directly, without metabolisation by the MTHFR enzyme.
Hyperhomocysteinemia in recurrent pregnancy loss (RPL)
Hyperhomocysteinemia in pregnant women has been associated with deep venous thrombosis, recurrent miscarriage, placental abruption, preeclampsia, neural tube defects, foetal growth restriction or other unfavourable conditions. About one in three patients of RPL have hyperhomocysteinemia, therefore, lowering homocysteine plasma levels can significantly help in improvement of pregnancy complications attributed to hyperhomocysteinemia. Quatrefolic® may help decrease homocysteine levels.
Fertility & Reproduction
MTHFR polymorphism plays a significant role in human fertility. It is associated with impaired female fecundity. Quatrefolic® bypasses folate metabolism disturbances and may improve female fertility and increase success rates in infertility treatment, as shown in a case series study (Servy et al. 2018). The study evaluated the effect of Quatrefolic® in couples with a long history of infertility with repeated foetal loss, premature ovarian failure or abnormal sperm parameters. Most of the women had previously been treated unsuccessfully with 5mg daily of folic acid. Both partners took 800mcg of Quatrefolic® which resulted in an overall pregnancy rate of 86.7%.
Research on the benefits of Quatrefolic®!
This study set out to determine if Quatrefolic® was effective at reducing homocysteine levels in people with a polymorphism at MTHFR C677T. Homocysteine is an amino acid that can build up in the blood and hyperhomocysteinaemia (high homocysteine levels) is the most common thrombophilia (a tendency towards blood clots). In pregnant women, this tendency towards blood clots increases her risk of miscarriage. According to the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), 1.5% of the population is homozygous (inherited from both parents) and 25% are heterozygous (inherited from one parent). RANZCOG state that this "thrombophilic tendency is minimised by an adequacy of folate, riboflavin (vitamin B2), vitamin B6 and vitamin B12". The participants in the study were 89 couples with fertility problems for at least 3 years. As expected, prior to treatment, homocysteine levels were higher in the homozygous patients than in the heterozygous patients. Couples were treated with 600mcg of Quatrefolic® for 3 months. Both groups were found to have a statistically significant reduction in homocysteine with a substantial reduction in the homozygous group. This study backs up the results of another study using Quatrefolic® conducted last year. Couples with MTHFR C677T polymorphisms experiencing recurrent miscarriages were treated with 800mcg of Quatrefolic®. You can find the results of the study here. References:
- Clément A, Menezo Y, Cohen M, Cornet D, Clément P. 5-Methyltetrahydrofolate reduces blood homocysteine level significantly in C677T methyltetrahydrofolate reductase single-nucleotide polymorphism carriers consulting for infertility. J Gynecol Obstet Hum Reprod. 2020
- RANZCOG, Vitamin and Mineral Supplementation and Pregnancy, PDF report published in November 2019.